KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Research & Development (2016 - 2025)

Sarepta Therapeutics has reported Research & Development over the past 15 years, most recently at $325.3 million for Q4 2025.

  • Quarterly results put Research & Development at $325.3 million for Q4 2025, up 62.71% from a year ago — trailing twelve months through Dec 2025 was $1.5 billion (up 89.19% YoY), and the annual figure for FY2025 was $1.5 billion, up 89.19%.
  • Research & Development for Q4 2025 was $325.3 million at Sarepta Therapeutics, up from $218.9 million in the prior quarter.
  • Over the last five years, Research & Development for SRPT hit a ceiling of $773.4 million in Q1 2025 and a floor of $139.1 million in Q3 2021.
  • Median Research & Development over the past 5 years was $209.1 million (2022), compared with a mean of $242.6 million.
  • Biggest five-year swings in Research & Development: decreased 26.95% in 2021 and later skyrocketed 285.96% in 2025.
  • Sarepta Therapeutics' Research & Development stood at $197.3 million in 2021, then increased by 8.37% to $213.8 million in 2022, then fell by 8.55% to $195.5 million in 2023, then grew by 2.27% to $200.0 million in 2024, then surged by 62.71% to $325.3 million in 2025.
  • The last three reported values for Research & Development were $325.3 million (Q4 2025), $218.9 million (Q3 2025), and $204.4 million (Q2 2025) per Business Quant data.